Molecules

DOTATOC

Target SSTR 2/3Class Peptide (somatostatin analogue, DOTA chelator)Other names edotreotide, DOTA-[Tyr³]octreotide

15ongoing trials
3radiolabelled forms
1approved products
1,186publications (PubMed)

Structure

Structure from the cited PubChem record (unlabelled ligand, or the labelled form when PubChem only describes that one). Conformer: RDKit (computed conformer, indicative). Rotate with the mouse or a finger.

Properties (PubChem)

Molecular formula
C65H92N14O18S2
Molar mass (g/mol)
1,421.6
Exact mass (Da)
1,420.6155
XLogP
-7.2
H-bond donors
17
H-bond acceptors
25
Rotatable bonds
26
Heavy atoms
99
InChIKey
RZHKDBRREKOZEW-AAXZNHDCSA-N
PubChem record
CID 158782 ↗
IUPAC name
2-[4-[2-[[(2R)-1-[[(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-4-[[(2R,3R)-1,3-dihydroxybutan-2-yl]carbamoyl]-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-19-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]-7,10-bis(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid
SMILES
C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)O)CC(=O)O)CC(=O)O)C(=O)N[C@H](CO)[C@@H](C)O)O

Radiolabelled forms

FormUseMolar mass (labelled form)Ongoing trialsMost advanced phaseApproval
[¹⁷⁷Lu]Lu-edotreotide (ITM-11) Syntheses and QC ↗Therapy—8Phase 3—
[⁹⁰Y]Y-DOTATOC Syntheses and QC ↗Therapy1,508.51Phase 1—
[⁶⁸Ga]Ga-DOTATOC Syntheses and QC ↗Imaging—6Phase 3DOTATATE / DOTATOC (Netspot, SomaKit TOC…) US EU FR

Ongoing trials · 15Open in the radar →

Atlas trials whose studied drug or title names this vector, with this radionuclide.

TrialPhaseStatusSponsorCountries
COMPETE · [177Lu]Lu-edotreotide (ITM-11)NCT03049189 · Gastroenteropancreatic NETsPhase 3Active, not recruitingITM Solucin GmbH14
COMPOSE · [177Lu]Lu-edotreotide (ITM-11)NCT04919226 · Gastroenteropancreatic NETsPhase 3Active, not recruitingITM Solucin GmbH10
START-NET · [177Lu]Lu-edotreotide (ITM-11)NCT05387603 · NETs and neuroendocrine carcinomas (other)Phase 3RecruitingLund University Hospital1
LEVEL · [177Lu]Lu-edotreotide (ITM-11)NCT05918302 · NETs and neuroendocrine carcinomas (other)Phase 3RecruitingGrupo Espanol de Tumores Neuroendocrinos4
[68Ga]Ga-DOTA-TATE/TOC/NOC2024-519505-35-00 · Gastroenteropancreatic NETsPhase 3RecruitingCentre Hospitalier Universitaire De Nantes1
DOTABREAST · [68Ga]Ga-DOTA-TATE/TOC/NOCNCT06611891 · BreastPhase 3RecruitingUniversity Hospital, Grenoble1
DOBATOC · [177Lu]Lu-edotreotide (ITM-11)NCT04917484 · NETs and neuroendocrine carcinomas (other)Phase 2RecruitingTine Gregersen, MD1
LUFOR · [177Lu]Lu-edotreotide (ITM-11)NCT06045260 · Pheochromocytoma / paragangliomaPhase 2RecruitingIstituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS1
PROMENADE · [177Lu]Lu-edotreotide (ITM-11)NCT04997317 · MeningiomaPhase 2RecruitingUniversity Hospital, Basel, Switzerland1
[68Ga]Ga-DOTA-TATE/TOC/NOC2023-504458-36-02 · BreastPhase 2RecruitingCentre Hospitalier Universitaire Grenoble Alpes1
KinLET · [177Lu]Lu-edotreotide (ITM-11)NCT06441331 · NETs and neuroendocrine carcinomas (other)Phase 1RecruitingITM Solucin GmbH3
[177Lu]Lu-edotreotide (ITM-11)NCT03044977 · Gastroenteropancreatic NETsPhase 1Active, not recruitingDavid Bushnell1
OPERANDI-NET · [68Ga]Ga-DOTA-TATE/TOC/NOCNCT06256705 · Gastroenteropancreatic NETsNo phaseRecruitingAssistance Publique - Hôpitaux de Paris1
GATEDOTA · [68Ga]Ga-DOTA-TATE/TOC/NOCNCT06467968 · Inflammatory diseasesNo phaseRecruitingCentral Hospital, Nancy, France1
[68Ga]Ga-DOTA-TATE/TOC/NOCNCT06773624 · Gastroenteropancreatic NETsNo phaseRecruitingEuropean Institute of Oncology1

Published results · 1

2026-07COMPETE · positiveVersus everolimus in progressive G1-G2 GEP-NETs, progression-free survival of 23.9 vs 14.1 months (HR 0.67), with half as many grade 3-4 adverse events (18% vs 40%).Lancet ↗

PublicationsAll publications in PubMed ↗

1,186 publications in PubMed for the query below; the most recent:

DOTATOC[tiab] OR edotreotide[tiab] OR "DOTA-TOC"[tiab]

  1. Unusual paraneoplastic thrombocytosis in small bowel neuroendocrine tumor responding to (177)Lu-DOTATATE JCEM Case Rep, 2026
  2. Radiopharmaceutical Therapy with [(177)Lu]Lu-DOTATATE in Refractory Meningiomas: Results from the French Multicenter MELUTE Cohort J Nucl Med, 2026
  3. Persistent Hyperinsulinemic Hypoglycemia After Insulinoma Surgery: Diagnostic Impact of GLP-1 Receptor PET/CT After Negative Conventional Imaging Case Rep Endocrinol, 2026
  4. EARL-based quantitative evaluation of administered activity reduction for [(68)Ga]Ga-DOTATOC PET/CT on a 32-cm axial FOV digital BGO system: Phantom analysis and retrospective list-mode clinical assessment Phys Med, 2026
  5. Nodal metastasis from an occult duodenal gastrinoma amid an overlap of xanthogranulomatous and type 1 autoimmune pancreatitis: A case report Radiol Case Rep, 2026
  6. Recurrent Metastatic Esthesioneuroblastoma: First-in-human α/β PRRT With Actinium-225/Lutetium-177-DOTA-LM3 SSTR Antagonist Achieving Partial Response After Failure of Lutetium-177-DOTATOC PRRT Clin Nucl Med, 2026
  7. Second-line (177)Lu-edotreotide shows promise in GEP NETs Nat Rev Clin Oncol, 2026
  8. High Somatostatin Receptor Expression in Alveolar Soft Part Sarcoma Detected by 68 Ga-DOTATOC PET/CT Clin Nucl Med, 2026

Sources: PubChem and PubMed (NCBI), ClinicalTrials.gov and CTIS registries, approvals recorded by the atlas. PubChem data as of 28 October 2026.

Cite this page

DOTATOC. Theranostic Atlas, LaRadiopharmacie.fr. Data as of 27 October 2026. https://theranosticatlas.com/molecule/dotatoc/ (accessed [date]).

A monitoring tool with no regulatory value: check every item at its source.